Semax Nasal Spray: Your Questions Answered by Our Team | telos rx
Clean modern desk workspace with laptop and monitor, focus theme
← Back to blog
cognitive health

Semax Nasal Spray: Your Questions Answered by Our Team

By TelosRX Clinical Team Updated

Semax nasal spray is a synthetic analogue of an ACTH fragment that has been studied for effects on BDNF and dopamine signaling in animal and early human research. It is not FDA-approved, requires a prescription, and is only appropriate for patients who qualify following review by a licensed provider.

Semax was developed at the Institute of Molecular Genetics in Russia in the 1980s and has been used clinically in Russia and Eastern Europe for neurological and cognitive applications. In the United States, it is not FDA-approved, and telos rx prescribes it as a compounded nasal spray for patients with a valid prescription. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the list of bulk substances for compounding, pending FDA rulemaking. That recommendation is not FDA approval of Semax as a drug. In October 2026, HHS also announced a temporary enforcement discretion policy that covers compounded intranasal Semax under strict conditions; more on that below.

Here is what the published research shows, and what our clinical review team hears most often from patients.


What Is Semax and How Does It Work?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide derived from the adrenocorticotropic hormone (ACTH) sequence residues 4 to 7, with a C-terminal Pro-Gly-Pro extension added to slow degradation. The N-acetyl version (N-acetyl semax, or "NA Semax") includes an additional acetyl group that is reported to improve stability.

The proposed mechanisms include:

  • BDNF upregulation: Semax has been reported to increase brain-derived neurotrophic factor (BDNF) expression in animal models, particularly in the hippocampus. BDNF is involved in neuronal survival, synaptic plasticity, and long-term potentiation, processes associated with learning and memory consolidation.
  • Dopamine system modulation: Semax appears to influence the mesolimbic dopamine pathway, potentially increasing dopamine receptor density and reducing dopamine catabolism in striatal tissue in preclinical models.
  • Serotonin and neuropeptide interactions: Some preclinical data suggests Semax interacts with enkephalin and serotonin systems, which may partially explain reported anxiolytic and mood-stabilizing effects in human observational contexts.

A 2006 rat study published in Brain Research (PMID 16996037) reported that Semax regulates BDNF and TrkB (the primary BDNF receptor) expression in the hippocampus, a plausible mechanism for its neurotrophic effects. This remains one of the most-cited mechanistic papers in the Semax literature.


Why Is the Nasal Route Used?

Like most peptides, Semax is degraded rapidly if taken orally: proteolytic enzymes in the GI tract break the peptide bonds before the molecule can reach systemic circulation in meaningful concentrations. Nasal administration bypasses this by allowing absorption through the nasal mucosa and, for some fraction of the dose, via the olfactory pathway, which provides more direct CNS access than peripheral circulation.

Intranasal peptide delivery is well-established for compounds like oxytocin, vasopressin, and insulin. Semax nasal spray follows the same pharmacokinetic rationale: fast absorption, partial systemic distribution, and potential for some direct nose-to-brain transport depending on formulation characteristics.


What Does the Research Actually Show?

The largest body of clinical literature on Semax comes from Russian research, primarily in patients with stroke, neurodegenerative disease, and cognitive impairment. This creates two important limitations for interpreting results in healthy users: the study populations differ, and many studies were conducted under regulatory and publication standards that differ from those required by journals indexed in MEDLINE or Cochrane.

What the evidence broadly supports:

  • Russian studies in stroke rehabilitation patients have reported changes in blood BDNF measures after intranasal Semax, though blood BDNF is an imperfect proxy for central changes.
  • Changes in attention and working memory measures were reported in several small trials in patients with cognitive impairment from vascular disease.
  • Animal studies have reported dose-dependent anxiolytic effects, though translation to human anxiety outcomes is uncertain.

What the evidence does not currently support: any assertion that Semax addresses, resolves, or reduces the incidence of any condition in otherwise healthy adults. No large randomized controlled trial meeting current FDA or EMA standards has been conducted for cognitive enhancement in healthy subjects.


Semax Dosage: What Protocols Are Commonly Used?

Published protocols vary widely in amount, timing, and schedule, and they are not treatment recommendations. At telos rx, your provider sets the dose and schedule after reviewing your intake. The table below compares the forms you will see discussed online.

Form What differs How it is studied Who sets the dose
Semax (standard) ACTH(4-7) fragment plus Pro-Gly-Pro Intranasal; amounts and schedules vary by study Your provider (telos rx prescribes Semax as a compounded nasal spray)
N-Acetyl Semax (NA Semax) Added N-terminal acetyl group Intranasal; limited published data Ask your provider which form is prescribed
N-Acetyl Semax Amidate Acetylated and C-terminally amidated Mostly preclinical and anecdotal data Ask your provider which form is prescribed

Amidate forms (C-terminal amidation) are described as more metabolically stable in preclinical data, though human comparison data is limited.


Side Effects and Safety Considerations

Semax has a relatively favorable tolerability profile in the published clinical literature, though rigorous long-term safety data in healthy Western populations is limited. Reported adverse effects include:

  • Transient nasal irritation or rhinorrhea at the administration site
  • Mild headache
  • Occasional reports of irritability or increased anxiety at higher doses, possibly related to dopaminergic stimulation
  • Fatigue or "mental tiredness" after prolonged use without cycling, in user-reported observational data

Semax is not known to be physically addictive, and no withdrawal syndrome has been documented in the published literature. That said, any compound that modulates dopamine signaling warrants careful monitoring in individuals with a history of mood disorders or substance use.

Patients currently on SSRIs, MAOIs, or other serotonergic or dopaminergic medications should discuss potential interactions with a licensed provider before use.


The July 2026 FDA Advisory Committee Vote: What It Means

In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the list of bulk drug substances that may be used in compounding, pending FDA rulemaking. This vote is advisory only. It does not:

  • Constitute FDA approval of Semax as a drug
  • Mean Semax is now FDA-approved for any indication
  • Change the requirement for a valid prescription and clinical oversight

On October 28, 2026, HHS announced an interim enforcement discretion policy for six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500). Under it, HHS does not intend to take enforcement action against state-licensed pharmacies or licensed physicians that compound these peptides with a valid prescription, as long as strict conditions are met: FDA-registered suppliers, lot-level testing, single-ingredient products, specific routes (for Semax, intranasal only), and adverse event reporting. It is temporary while FDA decides through rulemaking whether to add them to the list of substances that can be used in compounding. It is not FDA approval, and HHS can revisit it if safety or quality problems arise. See the Federal Register notice for details.

Final status still depends on FDA rulemaking. The FDA's bulk drug substances page tracks the status of bulk substance nominations.

telos rx follows these regulatory developments closely. Our peptide research blog covers updates as they occur.


How to Access Semax Nasal Spray Through telos rx

telos rx is an asynchronous telehealth service. You complete an online health intake; a US-licensed provider reviews your history, evaluates whether Semax may be appropriate for your goals, and communicates a decision, all without requiring a scheduled call or video visit. If prescribed, your provider sets the dose and schedule.

Compounded Semax nasal spray is not FDA-approved. A prescription is required, and approval is not guaranteed. Start your Semax intake at telos rx.

You may also find our guides on Semax peptide cognitive research and Selank peptide research useful for comparison. telos rx does not offer Selank.


Frequently Asked Questions

Is Semax legal in the United States?

Semax is not an FDA-approved drug, but it is not a controlled substance. It can be compounded for patients with a valid prescription, and telos rx prescribes it as a compounded nasal spray after provider review. In July 2026 an FDA advisory committee voted to recommend adding Semax to the list of bulk substances for compounding, but the vote is advisory only. In October 2026 HHS announced a temporary enforcement discretion policy covering compounded intranasal Semax under strict conditions while FDA rulemaking proceeds; it is not FDA approval.

How is Semax different from Selank?

Semax (ACTH-derived) and Selank (tuftsin-derived) are both synthetic neuropeptides with research in anxiety and cognition, but they differ in mechanism. Semax has a stronger BDNF-upregulation profile and more stimulating character; Selank leans toward GABAergic modulation and anxiolysis. Many clinicians consider them complementary rather than interchangeable. telos rx offers Semax, not Selank.

Can Semax be taken every day?

Published protocols differ, and some use cycles of use and rest based on the hypothesis that continuous use may downregulate BDNF responsiveness. There is no single standard schedule. At telos rx, your provider sets the dose and schedule for your clinical context.

Does Semax interact with antidepressants?

There are no well-documented drug-drug interaction studies between Semax and antidepressants in rigorous human trials. Given Semax's dopaminergic and serotonergic activity, patients on SSRIs, SNRIs, or MAOIs should discuss potential interactions with a licensed provider before use.

What is the difference between Semax and N-Acetyl Semax?

N-Acetyl Semax (NA Semax) has an acetyl group added to the N-terminus, which increases resistance to enzymatic degradation and may improve CNS penetration. Head-to-head clinical comparison data are limited. telos rx prescribes Semax as a compounded nasal spray; your provider can explain the formulation.

How quickly does Semax work?

There is no reliable timeline. Reports come mostly from small studies and anecdote, and effects in any individual are not predictable. Individual responses vary substantially, and your provider can discuss what to watch for.


telos rx Compliance Notice: telos rx is a LegitScript-certified telehealth service. Semax nasal spray is not FDA-approved and is not manufactured in an FDA-registered outsourcing facility unless otherwise specified. The July 2026 FDA advisory committee recommendation regarding the bulk substances list is advisory only and does not constitute drug approval. All prescribing decisions are made by licensed providers following independent asynchronous review of your health history. This article is for educational purposes only and does not constitute medical advice. Prescription products require a valid prescriber-patient relationship. Results vary by individual.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX